Sika initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of Sika (SXYAY) with a Buy rating and CHF 280 price target The firm expects Sika's top-line growth to revert to its more typical outperformance against its peers in the construction chemicals space, supported by 'a pickup in new products and a more constructive EU cycle,' and the analyst believes this re-acceleration in earnings growth can 'unlock valuation upside.'
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Vivoryon Therapeutics NV (FRA:05Y) Q1 2025 Earnings Call Highlights: Significant Reduction in ...
Research and Development Expenses: EUR1.2 million in Q1 2025, down from EUR7.4 million in Q1 2024. General and Administrative Expenses: EUR1.3 million in Q1 2025, compared to EUR2.1 million in Q1 2024. Net Loss: EUR2.4 million in Q1 2025, compared to EUR9.1 million in Q1 2024. Cash and Cash Equivalents: EUR7 million as of March 31, 2025, down from EUR9.4 million as of December 31, 2024. Warning! GuruFocus has detected 3 Warning Signs with FRA:05Y. Release Date: June 17, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Vivoryon Therapeutics NV (FRA:05Y) reported statistically significant and clinically meaningful improvements in kidney function with varoglutamstat in Phase 2 studies. The company has strengthened its intellectual property position with recent patent filings, including a new US composition of matter patent for varoglutamstat, supporting market exclusivity through 2044. Varoglutamstat has shown synergistic effects when combined with standard of care therapies in preclinical studies, enhancing its potential positioning in the market. The company has a clear development pathway for varoglutamstat, with plans to initiate a Phase 2b study in diabetic kidney disease. Vivoryon Therapeutics NV (FRA:05Y) has reduced its net loss significantly from EUR9.1 million in Q1 2024 to EUR2.4 million in Q1 2025, indicating improved financial management. The primary endpoint of cognition in the Phase 2 studies failed, which could impact the perception of varoglutamstat's overall efficacy. Vivoryon Therapeutics NV (FRA:05Y) reported a decrease in cash and cash equivalents from EUR9.4 million at the end of 2024 to EUR7 million as of March 31, 2025, which may affect future operations. The company is actively pursuing additional financing and partnership opportunities, indicating potential financial constraints. There is a significant unmet need for effective treatments for kidney diseases, and current therapies can only slow disease progression, highlighting the competitive and challenging market landscape. The company needs to ensure successful execution of its development plan, including the Phase 2b study, to maintain momentum and investor confidence. Q: What steps can Vivoryon Therapeutics take with its current cash position to prepare for the planned Phase 2b trial in diabetic kidney disease (DKD), and what are the optimal funding solutions for this trial? A: Frank Weber, CEO, explained that the company is in advanced protocol design discussions with CROs and experts, focusing on understanding the full development path through Phase 3. They are also considering study medication and financial aspects to prepare for the trial. Regarding funding, they are exploring partnership opportunities and other financing options to support the trial. Q: How are partnership discussions progressing, and are they reaching a more advanced state? A: Frank Weber, CEO, stated that Vivoryon is in ongoing conversations with interested pharma companies. They are assessing whether a partnership would be in the best interest of the company and its shareholders, given the unique data they have. Q: What proportion of patients in the US and Europe are currently receiving SGLT-2 inhibitors for DKD? A: Frank Weber, CEO, noted that SGLT-2 inhibitors are recommended in guidelines and are gaining traction, with approximately 30% to 35% of the potential population currently receiving them. The market penetration is increasing, although diagnosing patients in early stages remains a challenge. Q: Were there any key takeaways from the recent ERA Congress that could be incorporated into the Phase 2b trial design? A: Frank Weber, CEO, mentioned that the ERA Congress provided supportive feedback and insights into trial design. They are considering including patients with high proteinuria in Stage 3a, as these patients have a high risk of progression. Overall, the trial design is largely confirmed, with some adjustments to exclusion criteria. Q: What are the financial highlights for Vivoryon Therapeutics in the first quarter of 2025? A: Anne Doering, CFO, reported a net loss of EUR 2.4 million for Q1 2025, compared to EUR 9.1 million in Q1 2024. The company held EUR 7 million in cash as of March 31, 2025. The decrease in expenses was due to lower clinical and manufacturing costs following the ramp-down of previous studies. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Year-End Report 2024/2025
UPPSALA, SE / / June 18, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Positive development in the USA continues SEK t Q424/25 Q423/24 May-April 24/25 May-April 23/24 Net sales 2,332 1,899 8,619 7,290 Operating profit (loss) -20,341 -41,490 -85,839 -126,845 Profit (loss) for the period -20,766 -39,532 -87,624 -124,823 Earnings per share after dilution -0.21 -0.47 -0.95 -2.14 Number of shares at the end of the period 97,786,384 84,055,560 92,569,248 84,055,560 Cash and cash equivalents at the end of the period 24,415 79,407 24,415 79,407 Cash flow from operating activities -17,826 -25,251 -85,367 -114,575 Average number of employees 26 35 27 37 Biovica in brief - Treatment decisions with greater certainty Biovica's vision is: "Improved care for cancer patients." Biovica develops and commercializes the blood-based biomarker assay, DiviTum TKa, which enables early-stage evaluation of treatment effectiveness. The initial focus is on breast cancer. The initial focus area is metastatic breast cancer, however study results since 2024 show that DiviTum TKa can also serve as both a predictive and prognostic tool in the adjuvant treatment of early-stage breast cancer. DiviTum TKa has obtained FDA 510(k) clearance in the USA and has CE marking in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: Webcast:When: 18 June 2025, 3 PM to 4 PM CETWhere: register via: language: in English Significant events during the fourth quarter Biovica signed an agreement with Eurobio Scientific covering 60% of the European market Biovica has secured a new work order worth SEK 2.5 million for TKa testing services in the Pharma Services part of the business Biovica and Outcomes4Me have embarked on a new collaboration to empower patients with metastatic breast cancer to better understand how well their treatment is working DiviTum TKa data in combination with inflammation proteins presented at the AACR meeting enhance precision to predict efficacy of immunotherapy Significant events during the third quarter DiviTum TKa results presented at ASCO, the world's largest cancer conference Biovica signed new drug development agreement Extraordinary general meeting of Biovica International AB Biovica carried out a directed new issue of units for approximately SEK 16.4 million Biovica signed an agreement with US Biotech company in clinical phase Biovica secured a significant order for TKa testing services Biovica published the outcome of exercise of warrants from series TO3B. Biovica signed a master service agreement (MSA) with UK biotech company NewDivitum TKa data that significantly increases the market potential presented at SABCS Biovica signed an agreement with US healthcare and insurance giant Biovica's CLIA lab obtained a permit from the state of New York, which opens up the entire US market Biovica secured yet another significant order for TKa testing services Significant events after the end of the period Biovica is now collaborating with Tempus to expand the commercial reach of DiviTum TKa Biovica signed a significant Master Service Agreement (MSA) and first work under that agreement for SEK 4 million New data on DiviTum TKa use in three areas of cancer presented at ASCO Biovica secured three new assignments worth SEK 2.5 million in the Pharma Services part of the business Biovica announced financial targets subsequent to important partnership and commercial success Biovica resolved on a fully guaranteed rights issue of approximately SEK 80 million at SEK 0.63 per share Notice issued of extraordinary general meeting of Biovica International AB Biovica signed an agreement with its fifth Tier 1 biopharma company in the USA CEO's commentsImportant steps were made during the 2024/2025 financial year to establish DiviTum TKa as a standard approach to treatment monitoring in breast cancer. Strong clinical evidence, commercial success and new strategic partnerships have played a key role in solidifying our position in the US and European to the previous quarter, our sales in the USA increased by more than 25% in the fourth quarter and the positive trend has extended into the new fiscal year, following the recent close of our books. We have continued generating new clinical evidence for DiviTum TKa. The results from three cancer studies were presented at the 2025 ASCO Annual Meeting, which is the largest oncology conference in the world. The most impactful results, however, were those presented at the San Antonio Breast Cancer Symposium (SABCS) in December, where seven breast cancer studies - including two focused on early-stage disease - were shared. It opens up a new, very large market for us, with estimated market potential of up to USD 3 billion. There is a significant need within the healthcare industry to optimize and streamline the use of costly treatments - such as CDK4/6 inhibitors. This is where DiviTum TKa makes a real difference - providing evidence-based, cost-effective decision support. Further confirmation came in the form of a new agreement with a leading US healthcare and insurance giant with more than 10 million policyholders and annual revenue in excess of USD 100 billion. This organization - which serves as both a healthcare provider and health insurer - has observed that policyholders are at times prescribed costly treatments that are not always effective. The use of DiviTum TKa can enhance patient outcomes - while dramatically lowering costs for the organization. The agreement makes it possible to establish DiviTum TKa as one of their standard routines for breast cancer treatment. In May 2025, we also began a collaboration with the US-based diagnostics company Tempus AI, which will offer DiviTum TKa nationwide through its network of hundreds of sales representatives in the oncology field. Tempus AI has an impressive track record, with annual revenue growth exceeding 30%. Biovica's CLIA-certified laboratory will serve as a reference lab to Tempus AI, which will enable them to include DiviTum TKa in their collection of precision medicine solutions currently offered to more than 6,500 oncologists. Within our Pharma Services business, we continued to strengthen our relationships with the pharmaceutical industry throughout the year. Subsequent to the end of the period, we signed two new MSAs with Tier 1 (annual revenue exceeding USD 10 billion) pharmaceutical companies. An initial order of approximately SEK 5 million has already been received, with call-offs expected to take place over the next 2 to 3 years. This means that we now have 18 MSAs in place, including 5 with Tier 1 companies, representing a contract volume of approximately SEK 25 million in revenue to be recognized over the next 2 to 3 years as the services are delivered. This will be a key factor in achieving the financial targets that we have announced and an important step towards more comprehensive collaborations that could lead to new, customer-financed Companion Diagnostic (CDx) products. An additional key milestone this year was our new collaboration with Eurobio Scientific - a leading in vitro diagnostics company - which expands our commercial reach across Europe. It opens the door to eight key European markets, which together account for 60% of our priority EU markets. The combination of Eurobio's extensive hospital and laboratory network with our technology lays a strong foundation for increased test adoption across Europe. We are entering the new fiscal year with renewed confidence and increased market penetration - driven in part by the recent approval for our CLIA laboratory to offer DiviTum TKa to residents of New York State, as well as the growing interest we are seeing from both commercial partners and the clinical community. Our robust network of partners and growing presence in the clinical space position us well for continued growth, which is also reflected in the financial targets that we recently announced. The goal is to increase sales to SEK 50 million during the 2025/2026 fiscal year, derived primarily from the USA and Pharma Services. At the beginning of the financial year, we completed a targeted new share issue of SEK 16.4 million to support the continued commercialization and development of our operations. Participation came from both existing shareholders and new institutional investors. Subsequent to the end of the period there is also a rights issue underway and we are hoping for a high level of participation. Our assessment is that the guaranteed amount of SEK 80 million, based on the current business plan and in line with our previously communicated financial target, will sufficiently cover our needs until the point when the company is cash flow positive around the turn of the year 2026/2027. I would like to sincerely thank our employees, investors, clinical partners and everyone else who has contributed to our success during the year. Together, we will take the next steps toward improving treatment outcomes and quality of life for cancer patients throughout the world. Anders Rylander, CEO Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: This information is information that Biovica International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-06-18 08:00 CEST. Attachments Q4 2024 2025 Biovica Kommuniké 2025 04 30 Eng Final For Publikation SOURCE: Biovica International View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Weekly Picks: 💊 VLS' Solvable Headwinds, VOS' Multi-Year Growth, and ISRG's Valuation Concerns
Each week our analysts hand pick their favourite Narratives from the community ( ). This week's picks cover: 💊 Why Vita Life Science's is a solid business with solvable headwinds. 🇪🇺 How 2 massive tailwinds will drive multi-year growth for . ⚠️ Why strengths don't outweigh the valuation risks. 💡 Why we like it: This is a nuanced take on a steady but under-appreciated small-cap. The author doesn't ignore the headwinds (margin compression, FCF volatility) but frames them as solvable, giving this story both realism and recovery potential. 💡 Why we like it: This is a clear-eyed thesis that connects macro-scale infrastructure spending with company-specific catalysts like Sateba and smart digital upgrades. Their case blends revenue visibility, margin expansion, and a rising moat, making Vossloh a rare industrial that has both stability and upside. 💡 Why we like it: It's a well-structured growth thesis with clear timelines and layered catalysts. The blend of bullish conviction and valuation caution makes it a balanced take on a premium-priced healthcare innovator with serious staying power. This author thinks it's one for the watchlist. 🔔 Know when to act: Set the narrative valuations as your own fair value to know when to buy, hold or sell the stock. 🤔 Get answers: Ask the author any questions in the comments section. Feel free to like as well to support their work. ✨ Discover more Narratives: There are hundreds of other insightful stock narratives on our Community page . ✍️ Build an audience: Have your narrative seen by millions of investors, simply meet our Featuring criteria to go into the running! Disclaimer Simply Wall St analyst Michael Paige and Simply Wall St have no position in any of the companies mentioned. These narratives are general in nature and explore scenarios and estimates created by the authors. These narratives do not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimate's are estimations only, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Simply Wall St analyst Michael Paige and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
